Inclusion Criteria:

- Total body weight between 50 and 115 kg

- Hgb > 12 gm/dl

- Platelets > 100,000/μL

- ANC > 1000/μL

- Creatinine < 1.5 mg/dl

- SGPT and SGOT < 3 X the institutional upper limit of normal (ULN)

- Total bilirubin < 1.5 X the institutional ULN (subjects with a higher level of
bilirubin due to a familial metabolism will be considered on an individual basis)

- Life expectancy greater than 2 years

- Male subjects must agree to use adequate contraception (barrier method of birth
control; abstinence) prior to study entry and until study completion (i.e., at least
two weeks after dose of study drug)

- Ability to understand and the willingness to sign a written informed consent document

- Agree to refrain from use of selenium supplements while on study

Exclusion Criteria:

- Not willing to remain at RPCI, and in follow up, as required

- Presence of medical conditions, which in the opinion of the investigators, would
compromise either the subject, or the integrity of the data

- Individuals with a history of active liver or kidney disease within the past 6 months

- Treatment with an investigational drug within 30 days prior to the dose of study drug

- Use of prescription or nonprescription drugs, vitamins, or herbal supplements known
to change gastric acidity (e.g., H2-antagonists, proton pump inhibitors, antacids)
within 3 days of study drug administration

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to MSC (e.g. reaction to other selenium supplements)

- Subjects who have donated 1 unit of blood within 30 days prior to the first dose of
MSC

- Subjects with a known history of heavy metal exposure, such as lead, mercury, of
arsenic

- ECOG performance status > 1

- AUA total symptom score > 10 (or any individual symptom score of greater than or
equal to 4 will exclude the participant)